Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Health inequalities modular ...

that lay people, and organisations representing their interests, have opportunities to contribute to developing NICE guidance, advice and quality standards, and support their implementation, and that, ...

Abuse and neglect can have a long-lasting impact on the health and wellbeing of children and young people. It is important to know how to respond, and the evidence suggests that the following ...

Suggested remit: To appraise the clinical and cost effectiveness of Vosoritide within its marketing authorisation for treating achondroplasia in children.

A list of downloadable documents created during development.

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. The minutes of each evaluation committee meeting, which include the names of ...

Tebentafusp (Kimmtrak, Immunocore) is indicated 'as monotherapy for the treatment of human leukocyte antigen (HLA)‑A*02:01-positive adult patients with unresectable or metastatic uveal melanoma'. The ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...

More research is needed on electrically stimulated intravesical therapy to manage the symptoms of interstitial cystitis or overactive bladder in adults before it can be used in the NHS.

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...